Wellstat Therapeutics (Wellstat) and Sanofi-Aventis have entered into a global licensing agreement to develop, manufacture and commercialise PN2034, a first-in-class oral insulin sensitizer for the treatment of Type
Sinobiopharma has reported revenue of $1.29m for three months period which ended August 31, 2009, an increase of 39% from $931,203 for the comparable period previous year. Gross
APP Pharmaceuticals (APP), a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals, has received approval from the FDA to market Chlorothiazide Sodium for Injection, USP. APP expects to launch
Lonza and Alnara Pharmaceuticals (Alnara) have signed an agreement to manufacture Alnara’s lead product liprotamase. Liprotamase is a novel, oral, pancreatic enzyme replacement therapy (PERT) for patients with
The Scottish Medicines Consortium (SMC) has approved Tibotec’s once daily Prezista (darunavir) for use within NHS Scotland. Darunavir is a protease inhibitor (PI) indicated for the treatment of
The National Institute for Health and Clinical Excellence (NICE) has issued its Appraisal Consultation Document (ACD) rejecting oral Tyverb (lapatinib) in combination with capecitabine for the treatment of
Novavax and Xcellerex have entered into a strategic collaboration to accelerate the development of Novavax’s vaccine manufacturing process to commercial scale and begin immediate production of Novavax’s novel
Molecular Insight Pharmaceuticals (Molecular Insight) has executed an exclusive 10-year agreement to supply the Onalta 90-Y edotreotide radiotherapeutic to BioMedica Life Sciences. Onalta is a novel radiotherapeutic product
MacuSight has received Fast Track designation from the United States Food and Drug Administration (FDA) for Perceiva, the company’s proprietary ocular sirolimus product, for the treatment of diabetic
Laureate Pharma (Laureate) has signed a new biopharmaceutical development and manufacturing agreement with an undisclosed client. According to the agreement, Laureate will develop the process to manufacture a
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.